Repligen Corp.
http://www.repligen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repligen Corp.
Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
Dealmaking Quarterly Statistics, Q3 2021
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Atoll GmBH
- Avitide, Inc.
- C Technologies, Inc.
- Novozymes Biopharma Sweden AB
- TangenX Technology Corporation
- Polymem S.A.